Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
作者:Sahar B. Kandil、Christopher McGuigan、Andrew D. Westwell
DOI:10.3390/molecules26010056
日期:——
(AR) is a pivotal target for the treatment of prostate cancer (PC) even when the disease progresses toward androgen-independent or castration-resistant forms. In this study, a series of 15 bicalutamide analogues (sulfide, deshydroxy, sulfone, and O-acetylated) were prepared and their antiproliferative activity evaluated against four different human prostate cancer cell lines (22Rv1, DU-145, LNCaP, and
雄激素受体 (AR) 是治疗前列腺癌 (PC) 的关键目标,即使该疾病发展为不依赖雄激素或去势抵抗的形式。在这项研究中,制备了一系列 15 种比卡鲁胺类似物(硫化物、脱羟基、砜和 O-乙酰化),并评估了它们对四种不同的人前列腺癌细胞系(22Rv1、DU-145、LNCaP 和 VCap)的抗增殖活性。比卡鲁胺和恩杂鲁胺用作阳性对照。其中七种化合物在四种 PC 细胞系中显示出显着增强的抗癌活性。脱羟基类似物 (16) 是最具活性的化合物,IC50 = 6.59–10.86 µM。分子建模为硫化物类似物与其砜对应物相比的更高活性提供了合理的解释。